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We read with interest the paper by Nauta et al [1] since it relates to our own 
experience. The authors described a sub-cohort of oropharyngeal squamous cell 
carcinomas (OpSCCs) that were p16 positive (+) but HPV DNA negative (-) 
demonstrating poorer overall survival (OS) compared to p16+/HPVDNA+ individuals. 
We too have identified p16+/HPVDNA- cases within a UK population, a country with 
a higher prevalence of p16+ OpSCC than the Netherlands.   
 
In our study, 238 OpSCC specimens from a single centre were assessed using p16 
immunohistochemistry (CINtec®, Ventana Medical Systems). 153 cases (64.3%) 
were p16+ and were subsequently tested for high-risk (HR) HPV DNA using in-situ 
hybridisation (ISH, Ventana Medical Systems). Of the p16+ cases, 127 (83.0%) were 
HRHPV DNAISH+ whilst 26 (17.0%) were HRHPV DNAISH-. The p16+/HPVDNA- 
rate in our cohort was higher than that reported by Nauta et al (17.0% vs 12.4%) 
which may be explained by differences in sensitivity and specificity between DNAISH 
and PCR [2].  
 
Similar to Nauta et al, our p16+/HPVDNA- cases demonstrated improved OS 
compared to p16- individuals but showed poorer survival than p16+/HPVDNA+ 
patients (p<0.001; Figure 1A). Our p16+/HPVDNA- patients demonstrated better OS 
compared to the Dutch cohort and this too may be explained by the suboptimal 
sensitivity of DNAISH [2]. 
 
Since p16+/HPVDNAISH- cases could be due to either false positive p16 or false 
negative DNAISH, we used mRNAISH (RNAScope, ACDBio) as a third-tier test to 
resolve HPV status in p16+/HPVDNA- cases. This enabled us to further classify 15 
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(57.7%) and 11 (42.3%) cases as positive and negative for HRHPV, respectively. 
Interestingly, the OS of p16+/HPVDNAISH-/HPVRNAISH+ was similar to that of 
p16+/HPVDNAISH+ (Figure 1B), likely reflecting the greater sensitivity of mRNAISH 
[3]. Conversely, there was no significant difference in OS between 
p16+/HPVDNAISH-/HPVRNAISH- and p16- OpSCCs (p=0.626, Figure 1C). Our data 
therefore support the findings of Nauta et al in demonstrating poorer survival 
outcomes of p16+/HPVDNA- compared to p16+/HPVDNA+ OpSCC. We agree that it 
is important ‘to perform additional HPV DNA testing for predicting prognosis and 
when considering treatment de-intensification’ [1].  
 
Several authors have recently detailed the performance and utility of various 
laboratory HPV testing options in OpSCC [3, 4]. In this context it is important to note 
that inaccurate assessment of HPV status presents a hazard to patients enrolled in 
de-intensification trials by inappropriately assigning individuals to dose-reduction 
arms. In addition to exposing patients to sub-therapeutic regimes, the lack of 
specificity of p16 indicates that results of such de-intensification trials need to be 
interpreted with caution. To avoid such complications, we recommend a tiered 
algorithm utilising p16 immunohistochemistry, HR-HPV DNAISH and HR-HPV 
mRNAISH where the last provides an alternative to PCR in p16+/DNAISH- cases.  
 
It may be tempting to recommend mRNAISH as a single assay for HPV classification 
in OpSCCs, but a tiered algorithm with two or more strata almost always 
demonstrates greater utility in avoiding inaccurate results. Furthermore, the cost 
implications and lack of widespread availability restricts the routine use of mRNAISH 
the as the second-tier test in p16+ OpSCCs [5]. We therefore suggest that 
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mRNAISH be reserved as a third-tier test for OpSCCs that are p16+/DNAISH-. 
Patients with p16+ tumours that show negativity with both DNAISH and mRNAISH 
could represent a separate sub-group with a different prognosis altogether, and as 
such should be considered for exclusion from de-intensification trials.  
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Figure legend  
Figure 1. A. Kaplan-Meier curve for overall survival according to p16+/DNAISH+ 
(blue line), p16+/DNAISH- (green line), p16- (red line) status (Log rank test; χ2 = 
48.83; df = 2; p < 0.001). Significant difference in five-year overall survival was seen 
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between p16+/DNA ISH- (green line) and p16- (red line) cases (p = 0.023), as well 
as between p16+/DNA ISH- (green line) and p16+/DNA ISH+ (blue line) cases (p = 
0.022).  B. Kaplan-Meier curve for overall survival according to p16+/DNAISH+ (blue 
line) and p16+/DNAISH-/RNAISH+ (magenta line) status. (Log rank test; χ2 = 0.12; 
df = 1; p = 0.727). C. Kaplan-Meier curve for overall survival according to 
p16+/DNAISH-/RNAISH- (grey line) and p16- (red line) status. (Log rank test; χ2 = 
0.29; df = 1; p = 0.626). 
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Figure 1. A. Kaplan-Meier curve for overall survival according to p16+/DNAISH+ (blue line), p16+/DNAISH- 
(green line), p16- (red line) status (Log rank test; Χ2 = 48.83; df = 2; p < 0.001). Significant difference in 
five-year overall survival was seen between p16+/DNA ISH- (green line) and p16- (red line) cases (p = 
0.023), as well as between p16+/DNA ISH- (green line) and p16+/DNA ISH+ (blue line) cases (p = 
0.022).  B. Kaplan-Meier curve for overall survival according to p16+/DNAISH+ (blue line) and 
p16+/DNAISH-/RNAISH+ (magenta line) status. (Log rank test; Χ2 = 0.12; df = 1; p = 0.727). C. Kaplan-
Meier curve for overall survival according to p16+/DNAISH-/RNAISH- (grey line) and p16- (red line) status. 
(Log rank test; Χ2 = 0.29; df = 1; p = 0.626).  
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